WO2014178803A1 - A composition for use in the treatment of alcohol addiction - Google Patents

A composition for use in the treatment of alcohol addiction Download PDF

Info

Publication number
WO2014178803A1
WO2014178803A1 PCT/TR2013/000325 TR2013000325W WO2014178803A1 WO 2014178803 A1 WO2014178803 A1 WO 2014178803A1 TR 2013000325 W TR2013000325 W TR 2013000325W WO 2014178803 A1 WO2014178803 A1 WO 2014178803A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginsenoside
composition
treatment
alcohol addiction
addiction
Prior art date
Application number
PCT/TR2013/000325
Other languages
French (fr)
Inventor
Erdal Can ALKOÇLAR
Metehan YEŞIL
Original Assignee
Alkoçlar Erdal Can
Yeşil Metehan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkoçlar Erdal Can, Yeşil Metehan filed Critical Alkoçlar Erdal Can
Publication of WO2014178803A1 publication Critical patent/WO2014178803A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Definitions

  • the invention relates to a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction.
  • an object of the invention is to enable the body to repair the imbalance of dopamine and serotonin release in the body within a short time. Another object of the invention is to suppress the catecholamine secretion from the adrenal glands and reduce the production of the substance P having an important effect on addiction. Another object of the invention is to provide effectiveness in the permanent treatment of the alcohol addiction, owing to the ability to stimulate the AMPA receptor, the increase in the sensitivity of serotonin receptor, the suppression of the catecholamine secretion and the simultaneous reduction of the expression of the substance P.
  • the invention is a composition for use in the treatment of the alcohol addiction, said composition being obtained by the components selected from the group comprising 20-(s)-ginsenoside rg3, 20-(s)-B- ginsenoside rg3 that are used individually or in combinations.
  • the invention is a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction.
  • 20-(s)-ginsenoside rg3 and 20-(s)-B-ginsenoside rg3, which are active derivatives of ginsenoside rg3, a glucopyranoside derivative naturally contained by ginseng, enable the body to repair the imbalances in the secretion of dopamine and serotonin owing to the ability to stimulate the AMPA receptors, suppress the catecholamine secretion from the adrenal glands and reduce the production of the substance P having an important effect on addiction.
  • a permanent treatment is provided for the alcohol addiction, owing to the ability to stimulate the AMPA receptor, the increase in the sensitivity of serotonin receptor, the suppression of the catecholamine secretion and the simultaneous reduction of the expression of the substance P.
  • composition according to the invention contains 20-(s)-ginsenoside rg3, 20-(s)- B-ginsenoside rg3.
  • Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:
  • composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
  • Said invention also encompasses the use of said composition to enable the use of methylsalidroside and ginsenoside rg3 in the treatment of alcohol addiction and the manufacture thereof for this purpose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a composition formed for use in the treatment of the alcohol addiction.

Description

Description
A COMPOSITION FOR USE IN THE TREATMENT OF ALCOHOL ADDICTION Technical Field
The invention relates to a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction.
State of the Art
Today, tricyclic antidepressants, racetam derivatives, psychological group therapies and meetings are employed as the possible methods for the treatment of alcohol addiction.
The use of antidepressants and other psychotropic drugs usually aggravates the condition in the short term, and irreversibly aggravates the already existing depression caused by the alcohol addiction. Although partially successful results are obtained from the racetam derivatives, the alcohol addiction may relapse when their use is stopped. Group therapies suffer the instability of participation caused by the discomfort that the individuals feel about their situation.
As a result, the presence of the need for a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Object of the Invention
In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the body to repair the imbalance of dopamine and serotonin release in the body within a short time. Another object of the invention is to suppress the catecholamine secretion from the adrenal glands and reduce the production of the substance P having an important effect on addiction. Another object of the invention is to provide effectiveness in the permanent treatment of the alcohol addiction, owing to the ability to stimulate the AMPA receptor, the increase in the sensitivity of serotonin receptor, the suppression of the catecholamine secretion and the simultaneous reduction of the expression of the substance P. In order to achieve the aforesaid advantages, the invention is a composition for use in the treatment of the alcohol addiction, said composition being obtained by the components selected from the group comprising 20-(s)-ginsenoside rg3, 20-(s)-B- ginsenoside rg3 that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration. Detailed Description of the Invention
The invention is a composition formed for the use of methylsalidroside and ginsenoside rg3 in the treatment of the alcohol addiction. 20-(s)-ginsenoside rg3 and 20-(s)-B-ginsenoside rg3, which are active derivatives of ginsenoside rg3, a glucopyranoside derivative naturally contained by ginseng, enable the body to repair the imbalances in the secretion of dopamine and serotonin owing to the ability to stimulate the AMPA receptors, suppress the catecholamine secretion from the adrenal glands and reduce the production of the substance P having an important effect on addiction.
A permanent treatment is provided for the alcohol addiction, owing to the ability to stimulate the AMPA receptor, the increase in the sensitivity of serotonin receptor, the suppression of the catecholamine secretion and the simultaneous reduction of the expression of the substance P.
The composition according to the invention contains 20-(s)-ginsenoside rg3, 20-(s)- B-ginsenoside rg3.
Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:
1-99% 20-(s)-ginsenoside rg3,
99-1% 20-(s)-B-ginsenoside rg3.
The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.
Said invention also encompasses the use of said composition to enable the use of methylsalidroside and ginsenoside rg3 in the treatment of alcohol addiction and the manufacture thereof for this purpose.

Claims

1. A composition for use in the treatment of the alcohol addiction, said composition being obtained by the components selected from the group comprising 20-(s)-ginsenoside rg3, 20-(s)-B-ginsenoside rg3 that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 1-99% by weight 20-(s)-ginsenoside rg3.
3. A composition according to Claim 1 characterized in that it comprises 99-1% by weight 20-(s)-B-ginsenoside rg3.
4. Use of the components according to Claims 1 to 3 obtained individually or in combinations from the group consisting of 20-(s)-ginsenoside rg3, 20-(s)-B- ginsenoside rg3 for the manufacture of a composition for the treatment of alcohol addiction.
PCT/TR2013/000325 2013-04-29 2013-10-14 A composition for use in the treatment of alcohol addiction WO2014178803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201305046 2013-04-29
TR2013/05046 2013-04-29

Publications (1)

Publication Number Publication Date
WO2014178803A1 true WO2014178803A1 (en) 2014-11-06

Family

ID=49759517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000325 WO2014178803A1 (en) 2013-04-29 2013-10-14 A composition for use in the treatment of alcohol addiction

Country Status (1)

Country Link
WO (1) WO2014178803A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20119321U1 (en) * 2001-11-19 2002-05-29 mediWirk GmbH, 17489 Greifswald Pharmaceutical preparation
CN1911437A (en) * 2006-06-28 2007-02-14 杨贻方 Sobering-up beverage
WO2009094177A1 (en) * 2008-01-24 2009-07-30 Raptor Therapeutics Inc. Protopanaxadiol-type ginsenoside compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20119321U1 (en) * 2001-11-19 2002-05-29 mediWirk GmbH, 17489 Greifswald Pharmaceutical preparation
CN1911437A (en) * 2006-06-28 2007-02-14 杨贻方 Sobering-up beverage
WO2009094177A1 (en) * 2008-01-24 2009-07-30 Raptor Therapeutics Inc. Protopanaxadiol-type ginsenoside compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200744, Derwent World Patents Index; AN 2007-446853, XP002719524 *

Similar Documents

Publication Publication Date Title
GB2545368A (en) Diversion-resistant opioid formulations
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
WO2016090287A3 (en) Transdermal cannabinoid formulations
UY35334A (en) COMPOUNDS AND COMPOSITIONS AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVER
WO2012037410A3 (en) Estrogen receptor modulators and uses thereof
MX2019006221A (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery.
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
JP2017536398A5 (en)
GB201201314D0 (en) Composition
WO2017100700A3 (en) Peptides for renal therapy
AR074240A1 (en) COMPOUND 3- (4-CHLORO-2-FLUOROBENCIL) -2-METHYL-N- (5- METHYL-1H- PIRAZOL-3-IL) -8- (MORFOLINOMETIL) IMIDAZO (1,2-B) PIRIDAZIN -6- AMINA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC MYELOPROLIFERANT DISORDERS AND ASOCI CONDITIONS
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
MX2015015589A (en) Compositions and methods for delivery of hydrophobic active agents.
BR112017015487A2 (en) COMPOUND; COMPOSITION; METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL; AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL; ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL; METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2B OR IN RECEIVER 5-HT7, OR IN BOTH, IN AN INDIVIDUAL; METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN ADRENERGIC RECEPTORS IN AN INDIVIDUAL
EA201590030A1 (en) DRY POWDER INHALERS, CONTAINING CARRIER, EXCELLENT FROM LACTOSE, AND THIRD COMPONENT
AR097078A1 (en) COMBINATIONS THAT INCLUDE MABA AND CORTICOSTEROID COMPOUNDS, USE, KIT AND COMPOUND
WO2015116856A3 (en) Farnesoid x receptor antagonists
JP2015514739A5 (en)
EP4414037A3 (en) Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases
WO2014178803A1 (en) A composition for use in the treatment of alcohol addiction
EP4356964A3 (en) Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism
MX2017015047A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity.
WO2014014698A3 (en) Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13803303

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 05/02/2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13803303

Country of ref document: EP

Kind code of ref document: A1